齐拉西酮治疗儿童青少年精神分裂症的临床对照研究

目的观察齐拉西酮与利培酮对儿童青少年首发精神分裂症的临床疗效与安全性。方法 53例患者随机分为2组,分别用齐拉西酮(26例)或利培酮(27例)治疗,疗程均为8周。以临床疗效总评量表(CGI)、简明精神病评定量表(BPRS)评估有效性;用副反应量表(TESS)和血压、体重等评估安全性和耐受性。结果治疗8周后,BPRS评分,2组均明显低于治疗前,2组间BPRS减分率差异无统计学意义(P>0.05)。齐拉西酮组,未发现月经紊乱及体重增加;利培酮组,发现6例月经紊乱,4例体重增加。锥体外系不良反应,齐拉西酮组明显少于利培酮组(均P<0.05)。结论齐拉西酮治疗儿童青少年精神分裂症疗效确切,与利培酮相当;但不良反应较利培酮少。

Comparative clinical trial of ziprasidone in the treatment of child and adolescent schizophrenia

Objective To compare the efficacy and safety of ziprasidone and risperidone in the treatment of first onset schizophrenia.Methods Fifty inpatients aged 10-18 diagnosed with schizophrenia using ICD-10 criteria were treated with ziprasidone(26 patients) and risperidone(27 patients) for 8 weeks.Efficacy was assessed by using the clinical global impression(CGI) and the brief psychiatry rating scale(BPRS).The safety and tolerability were assessed by using the treatment emergent symptom scale(TESS).Important physiological parameters including blood pressure and weight were recorded.Results BPRS scores were significantly decreased in both groups after 8-week treatment,but there were no significant difference between two groups(P>0.05).However,the extrapyramidal reaction of ziprasidone was fewer than that of risperidone(P<0.05).Paramenia and weight gain was not found in patients treated with ziprasidone,but 6 patients with paramenia(P<0.05)and 4 patients with weight gain(P<0.05) were found among patients treated with risperidone.Conclusion Efficacy of ziprasidone is as same as that of risperidone for first onset child and adolescent schizophrenia,but extrapyramidal reaction,paramenia and weight gain are fewer.